MHC Class I Antigens In Malignant Cells: Immune Escape And Response To Immunotherapy

Author:   Natalia Aptsiauri ,  Angel Miguel Garcia-Lora ,  Teresa Cabrera
Publisher:   Springer-Verlag New York Inc.
Edition:   2013 ed.
Volume:   1
ISBN:  

9781461465423


Pages:   51
Publication Date:   22 February 2013
Format:   Paperback
Availability:   Manufactured on demand   Availability explained
We will order this item for you from a manufactured on demand supplier.

Our Price $145.17 Quantity:  
Add to Cart

Share |

MHC Class I Antigens In Malignant Cells: Immune Escape And Response To Immunotherapy


Add your own review!

Overview

Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy.  Precise identification of the mechanism leading to MHC class I defects  will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. ​  

Full Product Details

Author:   Natalia Aptsiauri ,  Angel Miguel Garcia-Lora ,  Teresa Cabrera
Publisher:   Springer-Verlag New York Inc.
Imprint:   Springer-Verlag New York Inc.
Edition:   2013 ed.
Volume:   1
Dimensions:   Width: 15.50cm , Height: 0.80cm , Length: 23.50cm
Weight:   1.066kg
ISBN:  

9781461465423


ISBN 10:   1461465427
Pages:   51
Publication Date:   22 February 2013
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand   Availability explained
We will order this item for you from a manufactured on demand supplier.

Table of Contents

Overview of MHC Class I Antigens.- HLA Class I Expression In Human Cancer.- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns.- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression.- Conclusion.

Reviews

Author Information

Teresa Cabrera Castillo, Ph.D., MD., is a Full Professor at the Department of Biochemistry, Molecular Biology, and Immunology at the University of Granada and a Medical Immunology Specialist at Hospital Universitario Virgen de las Nieves. Natalia Aptsiauri, Ph.D., MD., is a Senior Staff Scientist at the Department of Clinical Analysis and Immunology, University Hospital Virgen de las Nieves Angel Miguel Garcia Lora, Ph.D., is a Senior Staff Scientist at the Department of Clinical Analysis and Immunology, University Hospital Virgen de las Nieves Please see attached CVs for more detail.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

MRG2025CC

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List